Jci_page_head_homepage_01 Jci_page_head_homepage_02
Birgit Liliensiek, Markus A. Weigand, Angelika Bierhaus, Werner Nicklas, Michael Kasper, Stefan Hofer, Jens Plachky, Herman-Josef Gröne, Florian C. Kurschus, Ann Marie Schmidt, Shi Du Yan, Eike Martin, Erwin Schleicher, David M. Stern, Günter J. Hämmerling, Peter P. Nawroth, Bernd Arnold
Published in Volume 113, Issue 11
J Clin Invest. 2004; 113(11):1641–1650 doi:10.1172/JCI18704
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 5

RAGE–/– mice display normal inflammation in a model of DTH, and application of sRAGE blocks inflammation in DTH in WT and RAGE–/– mice. Age- and sex-matched WT and RAGE–/– mice were sensitized with mBSA. WT indicates C57BL/6 ∞ 129/Sv mice. Control groups were challenged with ovalbumin (OVA), and DTH groups, with mBSA. Mouse groups receiving sRAGE were pretreated by intraperitoneal injection of solvent or sRAGE 24 and 12 hours prior to and 6 and 12 hours after local challenge with mBSA. The DTH experiment was repeated three times and the DTH with sRAGE treatment was repeated two times with similar results (A). The mean clinical inflammation score represents a summary of two independent experiments. Twenty-four hours after footpad injection, mice were subjected to clinical scoring (see Methods). Standard error is given (± SEM), and P < 0.05 was considered to be statistically significant (*). WT, gray bars; RAGE–/–, white bars. (B) Representative pictures of hematoxylin and eosin–stained footpad sections of experimental groups; magnification, ∞400.